These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
80 related items for PubMed ID: 8852331
21. Protein kinase inhibitors as a therapeutic modality. Levitzki A. Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533 [Abstract] [Full Text] [Related]
22. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation. Nickischer D, Laethem C, Trask OJ, Williams RG, Kandasamy R, Johnston PA, Johnston PA. Methods Enzymol; 2006 Jun; 414():389-418. PubMed ID: 17110204 [Abstract] [Full Text] [Related]
23. Protein kinase inhibitors from the urea class. Dumas J. Curr Opin Drug Discov Devel; 2002 Sep; 5(5):718-27. PubMed ID: 12630292 [Abstract] [Full Text] [Related]
24. The development of benzimidazoles as selective rho kinase inhibitors. Sessions EH, Smolinski M, Wang B, Frackowiak B, Chowdhury S, Yin Y, Chen YT, Ruiz C, Lin L, Pocas J, Schröter T, Cameron MD, LoGrasso P, Feng Y, Bannister TD. Bioorg Med Chem Lett; 2010 Mar 15; 20(6):1939-43. PubMed ID: 20167489 [Abstract] [Full Text] [Related]
25. Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs. Schang LM. Antivir Chem Chemother; 2001 Mar 15; 12 Suppl 1():157-78. PubMed ID: 11594683 [Abstract] [Full Text] [Related]
26. Structure/function analysis of a dUTPase: catalytic mechanism of a potential chemotherapeutic target. Harris JM, McIntosh EM, Muscat GE. J Mol Biol; 1999 Apr 30; 288(2):275-87. PubMed ID: 10329142 [Abstract] [Full Text] [Related]
30. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Fischer PM. Curr Med Chem; 2004 Jun 30; 11(12):1563-83. PubMed ID: 15180564 [Abstract] [Full Text] [Related]
32. A tuned affinity-based staurosporine probe for in situ profiling of protein kinases. Cheng X, Li L, Uttamchandani M, Yao SQ. Chem Commun (Camb); 2014 Mar 18; 50(22):2851-3. PubMed ID: 24496501 [Abstract] [Full Text] [Related]
33. Purine Analogues as Kinase Inhibitors: A Review. Sharma S, Mehndiratta S, Kumar S, Singh J, Bedi PM, Nepali K. Recent Pat Anticancer Drug Discov; 2015 Mar 18; 10(3):308-41. PubMed ID: 26081925 [Abstract] [Full Text] [Related]
34. ATP site-directed kinase inhibitors. Denny WA. IDrugs; 1998 May 18; 1(1):10-2. PubMed ID: 18465492 [Abstract] [Full Text] [Related]
35. Enzymatic targets in virus chemotherapy. Helgstrand E, Oberg B. Antibiot Chemother (1971); 1980 May 18; 27():22-69. PubMed ID: 6996606 [No Abstract] [Full Text] [Related]
36. Proceedings of the 1st International Conference on Inhibitors of Protein Kinases. Warsaw, Poland, September 15-20, 1998. Pharmacol Ther; 1999 May 18; 82(2-3):109-449. PubMed ID: 10577161 [No Abstract] [Full Text] [Related]
37. Sensitivity of serum enzyme inhibitors to a variety of cancer chemotherapeutic agents. ELLIS FW, WEST PM. J Clin Invest; 1951 Jun 18; 30(6):547-57. PubMed ID: 14841254 [No Abstract] [Full Text] [Related]